Search Results - therapeutic+matter

407 Results Sort By:
PSMA-targeted Nanoparticles for Therapy of Prostate Cancer
PSMA-targeting nanoparticle for prostate cancer therapyJHU Ref #: C10180Value Proposition:·        Engineered nanoparticle system with potent urea-based PSMA inhibitor·        Drug loaded nanoparticle·        Specific and selective tumor cytotoxicity Unmet NeedProstate cancer affects millions of men globally and is a leading cause of cancer death in...
Published: 1/22/2026   |   Inventor(s): Martin Pomper, Ronnie Mease, Sachin Chandran, Sangeeta Ray, Samuel Denmeade
Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
Targeted chemo-immunotherapy delivery
Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...
Published: 1/22/2026   |   Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim
Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities
Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases
C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...
Published: 1/22/2026   |   Inventor(s): Niranjan Pandey, Elena Rosca, Corban Rivera, Jacob Koskimaki, Amir Tamiz, Aleksander Popel
Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Protein, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities
Nanoparticles for Topical Drug Delivery and Treatment of Hair Growth Conditions
Nanoparticles for Topical Drug Delivery and Treatment of Hair Growth ConditionsJHU REF: [C11686]Invention novelty: This invention is a nanoparticle for topical drug delivery targeting hair growth conditions. The particle may be an effective drug delivery tool for conditions such as hirsutism (excess hair) or alopecia (hair loss).Value PropositionThis...
Published: 1/22/2026   |   Inventor(s): Sewon Kang, Amanda Nelson, Joshua Wolfe, Jennifer Sample, Xiomara Calderon-Colon, Jason Benkoski, Mellisa Theodore, Julia Patrone, Marcia Patchan, Luis Garza
Keywords(s): Drug Delivery Vehicle, Lipid, Nanoparticles, Therapeutic Matter, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities
Anti-Fungal Drug Analogs to Treat Cancer by Preventing Angiogenesis and Hedgehog Pathway Activity
Value Proposition·      Itraconazole is in clinical trials for cancer treatment as it is known to have antiangiogenic activity and anti-Hedgehog pathway activity, but its use has been limited by its potent inhibition of the drug metabolizing enzyme CYP3A4·      The designed analog for itraconazole has greater antiangiogenic potency without CYP3A4 inhibition...
Published: 1/22/2026   |   Inventor(s): Jun Liu, Wei Shi, Kalyan Kumar Pasunooti, Wukun Liu, Ruojing Li, Sarah Head, Yingjun Li
Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Eye Disorders, Macular Degeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration
Polymeric particles for sustained delivery of multimodal peptide therapeutics
Value Proposition·      Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects·      Safety: use of nanoparticles reduces toxicity by confining peptide delivery to site of administration·      Flexible formulation approaches: system's...
Published: 1/22/2026   |   Inventor(s): Jordan Green, Aleksander Popel, Joel Sunshine, Ron Shmueli, Stephany Tzeng, Kristen Kozielski
Keywords(s): Biologics, Drug Delivery Vehicle, Nucleic Acid, Peptide, Polymers, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities
Cationic Polymers with Biphasic Biodegradation
Value Proposition·        Delivery Efficacy: Demonstrates more effective gene delivery to cancer associated fibroblasts (CAFs) or human primary fibroblasts than industry gold-standards such as Lipofectamine 2000 and polyethylenimine (PEI).·        Cargo Compatibility: Enables encapsulation and delivery of a wide range of cargos including, DNA, RNA,...
Published: 1/22/2026   |   Inventor(s): Stephany Tzeng, Ron Shmueli, Nupura Bhise, Joel Sunshine, Jordan Green
Keywords(s): Drug Delivery Vehicle, Polymers, Therapeutic Matter, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities
In vivo and in vitro Role of Lactosylceramide Synthase (LCS) in Angiogenesis and LCS (B1, 4GalT-V) as a Bio-marker for Human Colon Cancer
Description:   C10539: Use of Biomarker for Colon Cancer Diagnosis Value Proposition: ADVANTAGES • Colon cancer biomarker is directly included in panels of biomarkers for use in needle biopsies of colon tissue for early detection and diagnosis. • Colon cancer is the second largest mortality after cardiovascular disease. 90% of colorectal cancers...
Published: 1/22/2026   |   Inventor(s): Subroto Chatterjee
Keywords(s): Antagonists/Inhibitors, Biomarker, Cancers, Clinical Diagnostics, Colorectal Cancer, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer
Compositions and Biomarkers for Human Cancer and Methods of Use
Novel biomarkers for the detection and prognosis of several cancersJHU REF: C12506  Invention novelty: This invention has discovered high frequency mutations in the telomerase reverse transcriptase (TERT) promoter of certain cancers.   Value Proposition: Early detection is usually critical for the successful treatment of cancer, therefore there is...
Published: 1/22/2026   |   Inventor(s): Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Chetan Bettegowda, Yuchen Jiao, Darell Bigner, Hai Yan, Zachary Reitman, Patrick Killela
Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities
Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...
Published: 1/22/2026   |   Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton
Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer
1 2 3 4 5 6 7 8 9 10 ...
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum